Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 mRNA LNP Vaccine in Advanced Primary Hepatocellular Carcinoma
NCT07053072Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of PD-1 mRNA LNP vaccine in hepatocellular carcinoma (HCC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Adverse events at 1 month. Started Oct 2025; status: recruiting.
02
Drugs
PD-1 mRNA LNP vaccine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07053072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053072.